KYNTRA BIO (KYNB) director awarded 7,000 stock options at $7.13 strike

Rhea-AI Filing Summary

KYNTRA BIO, INC. director Michael Kauffman received a grant of stock options covering 7,000 shares of common stock. The options have an exercise price of $7.13 per share and expire on June 11, 2036. These options vest in four equal quarterly installments from the grant date, and his reported option holdings following this grant total 7,000 derivative securities.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Kauffman Michael

Role null

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	7,000	$0.00	--

Holdings After Transaction: Stock Option (Right to Buy) — 7,000 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Options granted: 7,000 options Exercise price: $7.13 per share Expiration date: June 11, 2036 +2 more

5 metrics

Options granted 7,000 options Stock Option (Right to Buy) granted to director

Exercise price $7.13 per share Exercise price of stock option grant

Expiration date June 11, 2036 Option expiration for 7,000-share grant

Post-grant derivative holdings 7,000 options Total derivative securities following transaction

Vesting schedule Four equal quarterly installments Measured from the date of grant per footnote

Key Terms

Stock Option (Right to Buy), exercise price, expiration date, derivative securities, +1 more

5 terms

Stock Option (Right to Buy) financial

"security_title: Stock Option (Right to Buy)"

exercise price financial

"conversion_or_exercise_price: 7.1300"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

expiration date financial

"expiration_date: 2036-06-11T00:00:00.000Z"

The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.

derivative securities financial

"derivativeTransactionCount: 1 derivative transaction"

Financial contracts whose value is tied to the price or performance of another asset, such as a stock, bond, commodity, index, or currency; examples include options, futures and swaps. They matter to investors because they let you protect against price swings, bet on future moves or gain larger exposure with less upfront cash—like using a lever or insurance policy on an investment—so they can amplify gains and losses and help manage portfolio risk.

vest in four equal quarterly installments financial

"The shares subject to the option shall vest in four equal quarterly installments"

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Kauffman Michael

(Last) (First) (Middle)

C/O KYNTRA BIO, INC.

350 BAY STREET, SUITE 100, #6009

(Street)

SAN FRANCISCO CALIFORNIA 94133

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
KYNTRA BIO, INC. [ KYNB ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/12/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$7.13	06/12/2026		A		7,000		(1)	06/11/2036	Common Stock	7,000	$0	7,000	D

Explanation of Responses:

1. The shares subject to the option shall vest in four equal quarterly installments measured from the date of grant.

	/s/ John Alden, Attorney-in-Fact	06/17/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did KYNTRA BIO (KYNB) director Michael Kauffman report in this Form 4?

Michael Kauffman reported receiving a grant of stock options for 7,000 shares of KYNTRA BIO common stock. These options were awarded as a compensation-related acquisition, rather than an open-market purchase or sale, and are held directly in his name.

What are the key terms of Michael Kauffman’s 7,000 KYNTRA BIO stock options?

The granted stock options cover 7,000 shares of common stock at an exercise price of $7.13 per share. They expire on June 11, 2036, giving a long exercise window, and represent a right to buy shares rather than an immediate ownership transfer.

How do Michael Kauffman’s KYNTRA BIO options vest over time?

The options vest in four equal quarterly installments measured from the grant date. This means 25% of the 7,000-share grant vests each quarter, aligning continued service with the gradual ability to exercise and acquire underlying common shares.

Did Michael Kauffman buy or sell KYNTRA BIO shares in the market?

The filing shows no open-market buys or sells of KYNTRA BIO shares. Instead, Kauffman received a compensation-related grant of stock options, classified as an acquisition under transaction code A, with no corresponding market transactions reported.

What is Michael Kauffman’s reported KYNTRA BIO option position after this grant?

Following the grant, the filing shows Kauffman holding 7,000 derivative securities in the form of stock options. This reflects the full 7,000-share option award, with no additional remaining derivative positions listed in the derivative summary section.